Simvastatin was cost-effective for reducing major vascular events in vascular disease or diabetes mellitus: COMMENTARY

Bloomfield, Hanna E.
November 2005
ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p80
Academic Journal
This article comments on a clinical study according to which simvastatin was cost-effective for reducing major vascular events in vascular disease or diabetes mellitus. Although the study by the HPS investigators is an elegant CEA based on an extremely important clinical trial, it will be of little relevance to most clinicians and policymakers. Nevertheless, this study's exploration of cost-effectiveness within specific risk groups is methodologically innovative and raises the interesting question of whether showing probable cost savings should drive recommendations about level of risk at which treatment should be initiated.


Related Articles

  • Simvastatin was cost-effective for reducing major vascular events in vascular disease or diabetes mellitus.  // ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p80 

    This article presents information on a clinical study according to which simvastatin was cost-effective for reducing major vascular events in vascular disease or diabetes mellitus. The study explored in patients with vascular disease or diabetes mellitus, what is the cost-effectiveness of...

  • Understanding why older people participate in clinical trials: the experience of the Scottish PROSPER participants. Tolmie, Elizabeth P.; Mungall, Moira M. B.; Louden, Greig; Lindsay, Grace M.; Gaw, Allan // Age & Ageing;Jul2004, Vol. 33 Issue 4, p374 

    Background: over the next 20 years it is anticipated that there will be a significant increase in those aged 75 and over, and a consequent increase in cardiovascular disease, cancer and chronic illness. As this shift takes effect, there will be an increased need for treatment strategies that are...

  • Rapidly rising clinical trial costs worry researchers.  // CMAJ: Canadian Medical Association Journal;2/3/2009, Vol. 180 Issue 3, p277 

    The article reports on the rapid increase in the cost of conducting clinical trials. According to the Tuft Center for the Study of Drug Development, the clinical trial cost of drug development in the 1980s and the 1990s has increased five times faster than preclinical cost. It is said that...

  • IV paricalcitol the clear winner in secondary hyperparathyroidism.  // PharmacoEconomics & Outcomes News;12/16/2006, Issue 518, p1 

    The article reports on the benefits of IV paricalcitol to patients with secondary hyperparathyroidism according to a study. Researchers modelled the costs and outcomes of using IV paricalcitol compared with oral calcitriol and oral and IV alfacalcidol for one year. IV paricalcitol was associated...

  • A prescription for improvement? An observational study to identify how general practices vary in their growth in prescribing costs. Avery, Anthony J; Rodgers, Sarah; Heron, Tara; Crombie, Robert; Whynes, David; Pringle, Mike; Baines, Darrin; Petchey, Roland // BMJ: British Medical Journal (International Edition);07/29/2000, Vol. 321 Issue 7256, p276 

    AbstractObjective: To identify how some general practices have low growth in prescribing costs relative to other practices.Design: Observational study.Setting: Trent region of England.Participants: 162 general practices: 54 with low growth in prescribing costs, 54 with average increases in...

  • Translating Epoetin Research Into Practice: The Role Of Government And The Use Of Scientific Evidence. Cotter, Dennis; Thamer, Mae; Narasimhan, Krishnan; Yi Zhang; Bullock, Kim // Health Affairs;Sep/Oct2006, Vol. 25 Issue 5, p1249 

    Spending for epoetin is Medicare's single largest drug expenditure. We chronicle the evolution of epoetin policy based on a lack of well-designed post-Food and Drug Administration approval studies demonstrating clinical benefit; congressional/federal agency reliance on clinical practice...

  • Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care: Recombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia. Cremieux, P-Y.; Finkelstein, S.N.; Berndt, E.R.; Crawford, J.; Slavin, M.B. // PharmacoEconomics;1999, Vol. 16 Issue 5, p459 

    Objective: To measure the cost effectiveness of a supportive care intervention when the no-treatment option is unrealistic in an analysis of recombinant human erythropoietin (epoetin) treatment for anaemic patients with cancer undergoing chemotherapy. Further, to assess whether quality-adjusted...

  • Management of diabetes in South Asian communities in the UK. Hill, Jillian // Primary Health Care;Apr2007, Vol. 17 Issue 3, p49 

    The article discusses some of the specific challenges related to the management of diabetes in South Asian patients in Great Britain. Its objective is to increase patients' awareness and be able to identify why there is an increased prevalence of diabetes in this population. The author outlines...

  • Atorvastatin cost saving for preventing cardiovascular events.  // PharmacoEconomics & Outcomes News;9/8/2007, Issue 536, p4 

    The article discusses research being done on the use of atorvastatin in preventing cardiovascular events. It references a study by R. J. Straka et al. published in the July 2007 issue of the "Current Medical Research and Opinion." The researchers from the U.S. and The Netherlands claimed that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics